Table 2 Treatments and clinical outcomes of patients with COVID-19
From: Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study
|  | All patients (n = 1190) | Survivor (n = 1033) | Non-survivor (n = 157) | p value |
|---|---|---|---|---|
Treatments, n (%) | ||||
 Antibiotic | 977 (87.7) | 859 (87.0) | 118 (92.9) | 0.0575 |
 Antifungal | 50 (4.5) | 35 (3.6) | 15 (11.8) | < 0.0001 |
 Antiviral | 681 (61.1) | 626 (63.4) | 55 (43.3) | < 0.0001 |
 Glucocorticoids | 289(25.9) | 213 (21.6) | 76 (59.8) | < 0.0001 |
 Oxygen therapy, n (%) |  |  |  | < 0.0001 |
  None | 203 (17.1) | 203 (19.7) | 0 (0.0) |  |
  Nasal cannula | 792(66.6) | 776 (75.1) | 16(10.2) |  |
  Mask oxygen | 27 (2.3) | 19 (1.9) | 7 (4.5) |  |
  High-flow nasal cannula | 60 (5.0) | 24 (2.3) | 36 (22.9) |  |
  Non-invasive mechanical ventilation | 62 (5.2) | 4 (0.4) | 58 (36.9) |  |
  Invasive mechanical ventilation | 42 (3.5) | 6 (0.6) | 36 (22.9) |  |
  ECMO | 4(0.3) | 0 | 4 (2.6) |  |
Outcomes | ||||
 Duration of MV (IQR), days | 5 (2.0, 8.0) | 6 (5.0, 9.0) | 4 (2.0,8.0) | 0.1563 |
 Duration of ICU stay (IQR), days | 6 (3.0, 10.5) | 7 (4.0, 11.0) | 5 (2.0, 9.0) | 0.0522 |
 Duration of in-hospital stay (IQR), days | 11 (7.0, 14.5) | 11 (8.0, 15.0) | 8 (4.0, 12.0) | < 0.0001 |
 In-hospital mortality, n (%) | 157 (13.2) | 0 (0.0) | 157 (100.0) | < 0.0001 |